Turalio

News
Merck drug for rare tumour hits phase 3 target

Merck drug for rare tumour hits phase 3 target

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 tr